Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
FATEthis companyFate Therapeutics, Inc.	$1.95	-0.85×	0.56×	17.56×	-1.16×	-121.9%	-94.1%	-2222.4%	-2051.1%	-65.8%	-51.4%	-96.0%	0.38×	-0.25×	0×	5.79×	0.0%	3	-8.27	1	C-
ABOSAcumen Pharmaceuticals, Inc.	$0.24	-1.06×	1.81×	0×	-0.9×	56.7%	0.0%	0.0%	0.0%	-172.3%	-121.7%	-90.5%	0.44×	0.19×	-29.32×	4.07×	0.0%	2	-11.67	2	C
ALECAlector, Inc.	$2.45	-1.12×	5.24×	7.63×	-0.99×	-108.0%	54.1%	-692.8%	-679.2%	-466.3%	-62.5%	-114.6%	1.18×	0.22×	0×	3.83×	0.0%	2	-7.33	2	C
CRBPCorbus Pharmaceuticals Holdings, Inc.	$3.47	-1.38×	0.73×	0×	-1.04×	-49.7%	0.0%	0.0%	0.0%	-53.2%	-57.2%	-59.5%	0.01×	0.34×	0×	8.07×	0.0%	1	-6.62	2	B-
INOInovio Pharmaceuticals, Inc.	$1.41	-0.96×	3.39×	1,248.52×	-0.57×	-63.4%	100.0%	-132871.3%	-130000.0%	-352.5%	-259.4%	-109.0%	0.39×	0.43×	0×	1.4×	0.0%	0	-54.95	1	C-
NKTXNkarta, Inc.	$1.29	-1.31×	0.44×	0×	-1.83×	-132.8%	0.0%	0.0%	0.0%	-33.3%	-31.2%	-65.7%	0.24×	-0.39×	0×	12.69×	0.0%	1	-2.81	2	C
Peer median	—	-1.12×	1.81×	0×	-0.99×	-63.4%	0.0%	0.0%	0.0%	-172.3%	-62.5%	-90.5%	0.39×	0.22×	0×	4.07×	0.0%	1	-7.33	2	—